ZA200600769B

ZA200600769B - Sulfonamide substituted imidazoquinolines

Info

Publication number: ZA200600769B
Application number: ZA200600769A
Authority: ZA
Inventors: George W Griesgraber
Original assignee: 3M Innovative Properties Co
Priority date: 2003-06-27
Filing date: 2006-01-26
Publication date: 2007-05-30
Also published as: WO2005003065A2; MY157827A; NZ544330A; AR044923A1; EP1638566A4; EP1638566A2; WO2005003065A3; AU2004253929A1; TW200514784A; RU2374246C2; IL172427A0; WO2005003064A3; BRPI0411916A; MXPA06000144A; CA2529322A1; CN1812789A; TW200511992A; WO2005003064A2; AR044922A1; RU2005138915A

Description

Sulfonamide Substituted Imidazoquinolines

Field of the Invention

This invention relates to imidazoquinoline compounds that have sulfonamide substitution at the 1-position and to pharmaceutical compositions containing the compounds. A further aspect of this invention relates to the use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases.

Background of the Invention

The first reliable report on the 1 H-imidazo[4,5-c]quinoline ring system, Backman etal, J. Org. Chem. 15, 1278-1284 (1950) describes the synthesis of 1-(6-methoxy-8- quinolinyl)-2-methyl-1H-imidazo[4,5-c]quinoline for possible use as an antimalarial agent. Subsequently, syntheses of various substituted 1H-imidazo[4,5-c] quinolines were reported. For example, Jain etal., J. Med. Chem. 11, pp. 87-92 (1968), synthesized the compound 1-[2-(4-piperidyl)ethyl]-1 H-imidazo[4,5-c]quinoline as a possible anticonvulsant and cardiovascular agent. Also, Baranov et al., Chem. Abs. 85, 94362 (1976), have reported several 2-oxoimidazo[4,5-c]quinolines, and Berenyictal, J.

Heterocyclic Chem. 18, 1537-1540 (1981), have reported certain 2-oxoimidazo[4,5- c]quinolines.

Certain 1 H-imidazo[4,5-c]quinolin-4-amines and 1- and 2-substituted derivatives thereof were later found to be useful as antiviral agents, bronchodilators and immunomodulators. These are described in, inter alia, U.S. Patent Nos. 4,689,338; 4,698,348; 4,929,624; 5,037,986; 5,268,376; 5,346,905; and 5,389,640, all of which are incorporated herein by reference.

There continues to be interest in the imidazoquinoline ring system, as seen for example in WO 98/30562, EP 894 797 and WO 00/09506. EP 894 797 discloses amide substituted imidazoquinoline compounds that are disclosed to be useful as immune response modifying compounds, while WO 00/09506 discloses imidazoquinoline compounds that contain a sulfonamide substituent wherein the sulfonamide nitrogen is part of a saturated heterocyclic ring. Despite these efforts, however, there is a continuing need for compounds that have the ability to modulate the immune response, by induction of cytokine biosynthesis or other mechanisms.

Summary of the Invention

We have found a new class of compounds that are useful in inducing cytokine biosynthesis in animals. Accordingly, this invention provides compounds of Formula I:

NH;

NZ NN goa

LJ x

R¢

M wherein R, R; and R; are as defined herein.

The compounds of Formula I are useful as immune response modifiers due to their ability to induce cytokine biosynthesis and otherwise modulate the immune reponse when administered to animals. This makes the compounds useful in the treatment of a variety of conditions such as viral diseases and tumors that are responsive to such changes in the immune response.

In one embodiment, compounds of the invention are selected from the group consisting of

N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1 -yl)butyl]benzenesulfonamide;

N-[4-(4-amino-2-propyl- 1 H-imidazo[4,5-c]quinolin- 1-yl)butyl]benzenesulfonamide;

N-[4-(4-amino-2-hexyl-1H-imidazo[4,5-c]quinolin-1 -yl)butyl]benzenesulfonamide;

N-[4-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin- 1-yl)butylJmethanesulfonamide;

N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)methanesulfonamide;

N-[4-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide;

N-[4-(4-amino-2-methyl-1 H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide;

N-[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propylJmethanesulfonamide;

N-[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]benzenesulfonamide;

N-[4-(4-amino-2-hexyl-1H-imidazo[4,5-c]quinolin-1-yl)butylJmethanesulfonamide;

N- {8-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1 - ylJoctyl} benzenesulfonamide;

N- {8-[4-amino-2-(2-methoxyethyl)- 1 H-imidazo([4,5-c]quinolin-1- ylJoctyl }methanesulfonamide;

N-[8-(4-amino-2-butyl- 1 H-imidazo{4,5-c]quinolin-1 -yloctyljmethanesulfonamide;

N-[3-(4-amino-2-butyl-1 H-imidazo[4,5-c)quinolin-1 -yl)propyl}-5- (dimethylamino)naphthalene-1 -sulfonamide;

N-[3-(4-amino-2-butyl-1 H-imidazo[4,5-c]quinolin-1 -yDpropyl}-4- methylbenzenesulfonamide;

N- {3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1- yljpropyl} methanesulfonamide;

N-[8-(4-amino-2-butyl- 1 H-imidazo[4,5-c]quinolin-1 -yl)octyl]benzenesulfonamide;

N-{3-[4-amino-2-(2-methoxyethyl)-1 H-imidazo[4,5-c]quinolin-1- yl]propyl} benzenesulfonamide;

N-[4-(4-amino-2-pentyl- 1 H-imidazo[4,5-c]quinolin- 1-yl)butylmethanesulfonamide;

N-[4-(4-amino-2-pentyl- 1H-imidazo[4,5-c]quinolin-1 -yl)butyl]benzenesulfonamide;

N-[8-(4-amino-1H-imidazo[4,5-c]quinolin-1 -yl)octylJmethanesulfonamide;

N- {3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1 -yl]propyl}-4- methylbenzenesulfonamide;

N-[4-(4-amino-2-pentyl-6,7,8,9-tetrahydro- 1 H-imidazo[4,5-c]quinolin-1- yl)butyljmethanesulfonamide;

N- {3-[4-amino-2-(ethoxymethyl)-1 H-imidazo[4,5-c]quinolin- 1- yllpropyl} methanesuifonamide;

N-{3-[4-amino-2-(2-methoxyethyl)- 1 H-imidazo[4,5-c]quinolin-1-yl]-2,2- dimethylpropyl} methanesulfonamide;

N- {3-[4-amino-2-(2-methoxyethyl)-1 H-imidazo[4,5-c]quinolin-1 -yl]propyl}-5- (dimethylamino)naphthalene-1-sulfonamide;

N-[3-(4-amino-2-methyl- 1 H-imidazo[4,5-c]quinolin-1 -yl)propyl]methanesulfonamide;

N- {3-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1 H-imidazo[4,5-c]quinolin-1- yl]propyl} methanesulfonamide;

N-{3-[4-amino-2-(cthoxymethyl)-6,7,8,9-tetrahydro-1 H-imidazo[4,5-c]quinolin-1- yl]propyl} methanesulfonamide;

N- {3-[4-amino-2-(3-phenoxypropyl)-1H-imidazo[4,5-c]quinolin-1 - yl]propyl} methanesulfonamide;

N- {4-[4-amino-2-(3-phenoxypropy!)-1H-imidazo[4,5-c]quinolin-1- yl]butyl}methanesulfonamide;

N-[4-(4-amino-2-methyl-6,7,8,9-tetrahydro- 1 H-imidazof4,5-c]quinolin-1- yl)butylJmethanesulfonamide hydrochloride;

N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-4- methylbenzenesulfonamide;

N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin- 1-yl)ethyljmethanesulfonamide; 1-[4-(1,1 -dioxidoisothiazolidin-2-yl)butyl]-2-(2-methoxyethyl)- 1 H-imidazo[4,5- c]quinolin-4-amine; 2-butyl-1-[4~(1,1-dioxidoisothiazolidin-2-yl)butyl]-1 H-imidazo[4,5-c]quinolin-4-amine;

N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-y1}-1,1- dimethylethyl} methanesulfonamide;

N-[4-(4-amino-2-methyl- 1 H-imidazo[4,5-c]quinolin-1-yl)butyl]ethanesulfonamide; 1-(2-amino-2-methylpropyl)-2-(ethoxymethyl)-1 H-imidazo[4,5-c]quinoline-4-amine; and

N-{4-[4-amino-2-(cyclopropylmethyl)- 1 H-imidazo[4,5-c]quinolin-1- yl]butyl} methanesulfonamide; or a pharmaceutically acceptable salt thereof.

In a particularly prefered embodiment, a compound or salt of the invention is N-{2- [4-amino-2-(ethoxymethyl)-1 H-imidazo[4,5-c]quinolin-1-yl]-1,1- dimethylethyl} methanesulfonamide or a pharmaceutically acceptable salt thereof. In addition to desirable formulation and toxicity properties, this compound has unexpectedly high IL-12 inducing activity relative to interferon (c) inducing activity.

The invention further provides pharmaceutial compositions containing a therapeutically effective amount of a compound or salt of Formula I or of the above embodiments and methods of inducing cytokine biosynthesis in an animal, treating a viral infection and/or treating a neoplastic disease in an animal by administering a effective amount of a compound or salt of Formula I or of the above embodiments to the animal.

In addition, methods of synthesizing compounds of Formula I and intermediates useful in the synthesis of these compounds are provided.

Detailed Description of the Invention

As mentioned earlier, the invention provides compounds of Formula I: - NH;

NZ NN

~ Na Ry (LJ

Rq

M

S wherein

R; is -alkyl-NR;-SO2-X-Rq, -alkenyl-NR;3-SOz—X-Ra4, or alkyl-NRs-SO2-R7;

X is a bond or —NRs-;

R, is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be 10 unsubstituted or substituted by one or more substituents selected from the group consisting of: -alkyl; -alkenyl, -aryl; 15 -heteroaryl; heterocyclyl; -substituted aryl; -substituted heteroaryl; -substituted heterocyclyl; 20 -O-alkyl, -O-(alkyl)o.i-aryl; -O-(alkyl)o.)-substituted aryl; -O-(alkyl)o.)-heteroaryl; -O-(alkyl)o.;-substituted heteroaryl, 25 -O-(alkyl)o.;-heterocyclyl; -O-(alkyl)o.;-substituted heterocyclyl;

-COOH; -CO-0O-alkyl; -CO-alkyl; -S(0)o-2 alkyl; -S(0)p-2 «(alkyl)o-1-aryl; -S(0)o.2 (alkyl).1-substituted aryl; -S(O)o.2 «(alkyl)o.1-heteroaryl; -S(0)o-2 (alkyl)o.1-substituted heteroaryl; -S(0)o2 (alkyl). 1-heterocyclyl; -S(0)o-2 (alkyl). -substituted heterocyclyl; ~(alkyl)o-1-NR3R3; «(alkyl)o.;-NR3-CO-O-alkyl; ~(alkyl)o.1-NR3-CO-alkyl; ~(alkyl)o.1-NR;3-CO-aryl; -(alkyl)o.1-NR;-CO-substituted aryl; -(alkyl)o.;-NR;3;-CO-heteroaryl; -(alkyl)o.1-NR;-CO-substituted heteroaryl; -Ns; -halogen; -haloalkyl; -haloalkoxy; -CO-haloalkoxy; -NO;

CN; -OH; -SH; and in the case of alkyl, alkenyl, or heterocyclyl, oxo;

R; is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl;

-substituted aryl; -heteroaryl; -substituted heteroaryl; - alkyl-O-alkyl; - alkyl-O- alkenyl; and - alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH; -halogen; -NR3)2; -CO-N(R3)z; -CO-Ci.10 alkyl; -CO-0-Ci.10 alkyl; - -N3; -aryl; -substituted aryl; -heteroaryl; -substituted heteroaryl; -heterocyclyl; -substituted heterocyclyl; -CO-aryl; -CO-(substituted aryl); -CO-heteroaryl; and -CO-(substituted heteroaryl); each Ry is independently selected from the group consisting of hydrogen and

Ci.oalkyl;

Rs is selected from the group consisting of hydrogen and Ci.10 alkyl, or Rq and Rg can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring;

Rg is selected from the group consisting of hydrogen and Ci.i0alkyl;

R; is selected from the group consisting of hydrogen and Cy. alkyl, wherein Rg and R; combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring;

nis 0 to 4 and each R present is independently selected from the group consisting of Cy.10 alkyl, Cio alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.

Preparation of the Compounds

Imidazoquinolines of the invention can be prepared according to Reaction Scheme

I where R, R;, R; and n are as defined above.

In step (1) of Reaction Scheme I a 4-chloro-3-nitroquinoline of Formula II is reacted with an amine of Formula RNH; where R, is as defined above to provide a 3- nitroquinolin-4-amine of Formula II. The reaction can be carried out by adding amine to a solution of a compound of Formula II in a suitable solvent such as chloroform or dichloromethane and optionally heating. Many quinolines of Formula II are known compounds (see for example, U.S. Patent 4,689,338 and references cited therein).

In step (2) of Reaction Scheme 1 a 3-nitroquinolin-4-amine of Formula III is reduced to provide a quinoline-3,4-diamine of Formula IV. Preferably, the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon or palladium on carbon. The reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as isopropyl! alcohol or toluene.

In step (3) of Reaction Scheme I a quinoline-3,4-diamine of Formula IV is reacted with a carboxylic acid or an equivalent thereof to provide a 1 H-imidazo[4,5-c]quinoline of

Formula V. Suitable equivalents to carboxylic acid include acid halides, orthoesters, and 1,1-dialkoxyalkyl alkanoates. The carboxylic acid or equivalent is selected such that it will provide the desired R; substituent in a compound of Formula V. For example, triethyl orthoformate will provide a compound where R; is hydrogen and triethyl orthoacetate will provide a compound where R; is methyl. The reaction can be run in the absence of solvent or in an inert solvent such as toluene. The reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.

In step (4) of Reaction Scheme I a 1 H-imidazo[4,5-c]quinoline of Formula V is oxidized to provide a 1H-imidazo[4,5-c]quinoline-SN-oxide of Formula VI using a conventional oxidizing agent that is capable of forming N-oxides. Preferred reaction conditions involve reacting a solution of 2 compound of Formula V in chloroform with 3- chloroperoxybenzoic acid at ambient conditions.

In step (5) of Reaction Scheme I a 1 H-imidazo[4,5-c]quinoline-5N-oxide of

Formula VI is aminated to provide a 1 H-imidazo[4,5-c]quinolin-4-amine of Formula VII which is a subgenus of Formula I. Step (5) involves (i) reacting a compound of Formula

VI with an acylating agent and then (ii) reacting the product with an aminating agent. Part (i) of step (5) involves reacting an N-oxide of Formula VI with an acylating agent.

Suitable acylating agents include alkyl- or arylsulfonyl chlorides (e.g., benezenesulfonyl chloride, methanesulfonyl chloride, p-toluenesulfonyl chloride). Arylsulfonyl chlorides are preferred. Para-toluenesulfonyl chloride is most preferred. Part (ii) of step (5) involves reacting the product of part (i) with an excess of an aminating agent. Suitable aminating agents include ammonia (e.g., in the form of ammonium hydroxide) and ammonium salts (e.g., ammonium carbonate, ammonium bicarbonate, ammonium phosphate). Ammonium hydroxide is preferred. The reaction is preferably carried out by dissolving the N-oxide of Formula VI in an inert solvent such as dichloromethane, adding the aminating agent to the solution, and then slowly adding the acylating agent. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Alternatively, step (5) may be carried out by (i) reacting an N-oxide of Formula VI with an isocyanate and then (ii) hydrolyzing the resulting product. Part (i) involves reacting the N-oxide with an isocyanate wherein the isocyanato group is bonded to a carbonyl group. Preferred isocyanates include trichloroacetyl isocyanate and aroyl isocyanates such as benzoyl isocyanate. The reaction of the isocyanate with the N-oxide is carried out under substantially anhydrous conditions by adding the isocyanate to a solution of the N-oxide in an inert solvent such as chloroform or dichloromethane. Part (ii) involves hydrolysis of the product from part (i). The hydrolysis can be carried out by conventional methods such as heating in the presence of water or a lower alkanol optionally in the presence of a catalyst such as an alkali metal hydroxide or lower alkoxide.

Reaction Scheme

N x NO, N EN NO, N Xn NH, — | _— | _ 7 cl (1) ZTE) NH

Rn Ra k, R n R, ] m v (3)

NH, _

O.. + N N

N XD N, N AN 2 N 2 -— | »R, =— | >R,

A 5) Pa 4) 7 N

Ry R, Ro R, Ro R,

Vil \v| ) \'

Compounds of the invention where the R, substituent contains a sulfonamide can also be prepared according to Reaction Scheme IT where R, R,, Ry and n are as defined above and m is 1-20.

In Reaction Scheme II an aminoalky! substituted 1H-imidazo[4,5-c]quinolin-4- amine of Formula VIII is reacted with a sulfonyl chloride of Formula IX to provide a compound of Formula X which is a subgenus of Formula I. The reaction can be run at ambient temperature in an inert solvent such as dichloromethane in the presence of a base such as pyridine or N,N-diisopropylethylamine. Many 1 H-imidazo[4,5-c]quinolin-4- amines of Formula VIII are known compounds, see for example US Patent 6,069,149 (Namba); others can be readily prepared using known synthetic methods. Many sulfonyl chlorides of Formula IX are commercially available; others can be readily prepared using known synthetic methods. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Reaction Scheme II

NH, NH, : Di ha + io — : pi Se,

Rn © Ra EH

NH, NH vill 1X X 0=$=0

R,

Compounds of the invention where the R, substituent contains a sulfonamide can also be prepared according to Reaction Scheme III where R, Ra, Ry and n are as defined above and m is 1-20.

In Reaction Scheme III an aminoalkyl substituted 1 H-imidazo[4,5-c]quinolin-4- amine of Formula VIII is reacted with a sulfonic anhydride of Formula X1 to provide a compound of Formula X which is a subgenus of Formula I. The reaction can be run at ambient temperature in an inert solvent such as dichloromethane in the presence of a base such as pyridine or N,N-diisopropylethylamine. Alternatively, the reaction can be run at ambient temperature in acetonitrile. Many sulfonic anhydrides of Formula XI are commercially available; others can be readily prepared using known synthetic methods.

The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Reaction Scheme III

NH, NH, : Di Se, + RB-0-0— R, — : 7 “Nr, oO © Z Nl

Rn (CHa)m Rn (CHI

NH, NH vill XI X 0=3$=0

R,

Tertiary sulfonamides of the invention can be prepared according to Reaction

Scheme IV where R, Ry, Rj, Ry and n are as defined above and m is 1-20.

In Reaction Scheme IV a 1H-imidazo[4,5-c]quinolinyl sulfonamide of Formula X is reacted with a halide of Formula XII to provide a compound of Formula XIII which is a subgenus of Formula I. The reaction can be carried out at ambient temperature by adding sodium hydride to a solution of a compound of Formula X in N,N-dimethyl formamide and then adding the halide. Many halides of Formula XII are commercially available; others can be readily prepared using known synthetic methods. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Reaction Scheme IV

NH, NH, : Dl Se, + Rpts — : Di Sr,

Rn Hm Ra Hm

NH N

X 0=5=0 Xi xi fox®

R, R,

Compounds of the invention where R, contains a sulfamide group can be prepared according to Reaction Scheme V wherein R, Rz, R4, Rs and n are as defined above and m 1s 1-20.

In step (1) of Reaction Scheme V an aminoalkyl substituted 1H-imidazo[4,5- c]quinolin-4-amine of Formula VIII is reacted with sulfuryl chloride to generate in situ a sulfamoyl chloride of Formula XIV. The reaction can be carried out by adding a solution of sulfuryl chloride in dichloromethane to a solution of a compound of Formula VIII in dichloromethane in the presence of one equivalent of 4-(dimethylamino)pyridine. The reaction is preferably carried out at a reduced temperature (-78°C). Optionally, after the addition is complete the reaction mixture can be allowed to warm to ambient temperature.

In step (2) of Reaction Scheme V an amine of Formula RsR NH is reacted with the sulfamoy] chloride of Formula XIV to provide a 1 H-imidazo[4,5-c]quinolinyl sulfamide of

Formula XV which is a subgenus of Formula I. The reaction can be carried out by adding a solution containing 2 equivalents of the amine and 2 equivalents of triethylamine in dichloromethane to the reaction mixture from step (1). The addition is preferably carried out at a reduced temperature (-78°C). After the addition is complete the reaction mixture can be allowed to warm to ambient temperature. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Reaction Scheme V

NH, NH, NH,

Ne 20 Ne TI A

Z N 1) = N (2) Z N

Ra CHam Rn (CHa RA (CH)

NM, HN, HN, 0=%]=0 0=%=0

Vili XIV Cl XV N

R/ “R,

Tetrahydroimidazoquinolines of the invention can be prepared according to

Reaction Scheme VI where Ry, Rs, Rs, and Rs are as defined above and m is 1-20.

In step (1) of Reaction Scheme VI an aminoalkyl substituted 1H-imidazo{4,5- c]quinolin-4-amine of Formula XV1is reduced to provide an aminoalkyl substituted 6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine of Formula XVII. Preferably the reduction is carried out by suspending or dissolving the compound of Formula XVI in trifluoroacetic acid, adding a catalytic amount of platinum (IV) oxide, and then subjecting the mixture to hydrogen pressure. The reaction can conveniently be carried out on a Parr apparatus. The product or a salt thereof can be isolated using conventional methods.

In step (2a) of Reaction Scheme VI an aminoalky! substituted 6,7,8,9-tetrahydro- 1 H-imidazo[4,5-c]quinolin-4-amine of Formula XVII is reacted to provide a compound of

Formula XVIII which is a subgenus of Formula I. When Rj is hydrogen, the reaction can be carried out in one step according to the methods described in Reaction Schemes II and

II above using a tetrahydroimidazoquinoline of Formula XVII in place of the imidazoquinoline of Formula VIII. When Rj is other than hydrogen, the reaction can be carried out in two steps with step one being carried out according to the methods of

Reaction Schemes II and III and step two being carried out according to the method of

Reaction IV using the tetrahydroimidazoquinoline analog of the imidazoquinoline. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

In step (2b) of Reaction Scheme VI an aminoalkyl substituted 6,7,8,9-tetrahydro- 1 H-imidazo[4,5-c]quinolin-4-amine of Formula XVII is reacted to provide a compound of

Formula XIX which is a subgenus of Formula I. The reaction can be carried out according to the method described in Reaction Scheme V using a tetrahydroimidazoquinoline of

Formula XVII in place of the imidazoquinoline of Formula VIII The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Reaction Scheme VI

NH,

NSN

»R,

NH, NH, _ A N

NTN NTN CH

TOR NR ® (Hm

ZN (1) ZN N. .O xviii R,” PEN (CHI (CH) 0” “R,

NH, NH, 2b

XVI XVII \¢ J.

NTN

DP JR

[ (CH) m

HN. _-O xx SH 0 N=,

Rs

Tetrahydroimidazoquinolines of the invention can also be prepared according to

Reaction Scheme VII where R, Ra, R3, Ry, Rs and n are as defined above and m is 1-20.

In step (1) of Reaction Scheme VII a 6,7,8,9-tetrahydro-1H-imidazo[4,5- c]quinolinyl fert-butylcarbamate of Formula XX is hydrolyzed to provide an aminoalkyl substituted 6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine of Formula XXI. The reaction can be carried out dissolving the compound of Formula XX in a mixture of trifluoroacetic acid and acetonitrile and stirring at ambient temperature. Altematively, the compound of Formula XX can be combined with dilute hydrochloric acid and heated on a steam bath. Tetrahydro-1H-imidazo[4,5-c]quinolinyl tert-butylcarbamates of Formula XX can be prepared using the synthetic route disclosed in U.S. Patent 5,352,784 (Nikolaides).

The product or a salt thereof can be isolated using conventional methods.

Steps (2a) and (2b) can be carried out in the same manner as in Reaction Scheme

V1

Reaction Scheme VII

NH, ! Ts,

NH, NH, es Z~N

NSN NSN - Er)

AR Te PN ree

R R | Xin R78 n (CHa n (CH m 0" "R,

XX To xxi a A NH, x —N xX Jp

Rn Hi

HN. s©

XXII 0” Ng 4 4

Some compounds of Formula I can be readily prepared from other compounds of

Formula I. For example, compounds wherein the R4 substituent contains a chloroalkyl group can be reacted with an amine to provide an R4 substituent substituted by a secondary or teriary amino group; compounds wherein the Ry substituent contains a nitro group can be reduced to provide a compound wherein the Ry substituent contains a primary amine.

As used herein, the terms “alkyl”, “alkenyl”, “alkynyl” and the prefix “.alk” are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e. cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to 20 carbon atoms, with alkenyl and alkynyl groups containing from 2 to 20 carbon atoms.

Preferred groups have a total of up to 10 carbon atoms. Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopentyl, cyclohexyl and adamantyl.

The term “haloalkyl” is inclusive of groups that are substituted by one or more halogen atoms, including groups wherein all of the available hydrogen atoms are replaced by halogen atoms. This is also true of groups that include the prefix ‘“haloalk-".

Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like.

The term “aryl” as used herein includes carbocyclic aromatic rings or ring systems.

Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl. The term “heteroaryl” includes aromatic rings or ring systems that contain at least one ning hetero atom (e.g., O, S, N). Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, tetrazolyl, imidazo, pyrazolo, thiazolo, oxazolo, and the like. “Heterocyclyl” includes non-aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N). Exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, and the like.

Unless otherwise specified, the terms “substituted cycloalkyl”, “substituted aryl”, “substituted heteroaryl” and “substituted heterocyclyl” indicate that the rings or ring systems in question are further substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, alkylthio, hydroxy, halogen, haloalkyl, haloalkylcarbonyl, haloalkoxy (e.g., trifluoromethoxy), nitro, alkylcarbonyl, alkenylcarbonyl, arylcarbonyl, heteroarylcarbonyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocycloalkyl, nitrile, alkoxycarbonyl, alkanoyloxy, alkanoylthio, and in the case of cycloalkyl and heterocyclyl, oxo.

In structural formulas representing compounds of the invention certain bonds are represented by dashed lines. These lines mean that the bonds represented by the dashed line can be present or absent. Accordingly, compounds of Formula I can be either imidazoquinoline compounds or tetrahydroimidazoquinoline compounds.

The invention is inclusive of the compounds described herein in any of their pharmaceutically acceptable forms, including isomers such as diastereomers and enantiomers, salts, solvates, polymorphs, and the like.

Pharmaceutical Compositions and Biological Activity

Pharmaceutical compositions of the invention contain a therapeutically effective amount of a compound of Formula I in combination with a pharmaceutically acceptable carrier.

As used herein, the term “a therapeutically effective amount” means an amount of the compound sufficient to induce a therapeutic effect, such as cytokine induction, antiturnor activity and/or antiviral activity. Although the exact amount of active compound used in a pharmaceutical composition of the invention will vary according to factors known to those of skill in the art, such as the physical and chemical nature of the compound as well as the nature of the carrier and the intended dosing regimen, it is anticipated that the compositions of the invention will contain sufficient active ingredient to provide a dose of about 100ng/kg to about S0mg/kg, preferably about 10pg/kg to about 5mg/kg of the compound to the subject. Any of the conventional dosage forms may be used, such as tablets, lozenges, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmucosal patches and the like.

The compounds of the invention have been shown to induce the production of certain cytokines in experiments performed according to the tests set forth below. These results indicate that the compounds are useful as immune response modifiers that can modulate the immune response in a number of different ways, rendering them useful in the treatment of a variety of disorders.

Cytokines that may be induced by the administration of compounds according to the invention generally include interferon-a (IFN-a) and tumor necrosis factor-a (TNF-a) - as well as certain interleukins (IL). Cytokines whose biosynthesis may be induced by compounds of the invention include IFN-a,, TNF-a, IL-1, 6,10 and 12, and a variety of other cytokines. Among other effects, cytokines inhibit virus production and tumor cell growth, making the compounds useful in the treatment of viral diseases and tumors.

In addition to the ability to induce the production of cytokines, the compounds of the invention affect other aspects of the innate immune response. For example, natural killer cell activity may be stimulated, an effect that may be due to cytokine induction. The compounds may also activate macrophages, which in turn stimulates secretion of nitric oxide and the production of additional cytokines. Further, the compounds may cause proliferation and differentiation of B-lymphocytes. '

Compounds of the invention also have an effect on the acquired immune response.

For example, although there is not believed to be any direct effect on T cells or direct induction of T cell cytokines, the production of the T helper type 1 (Th1) cytokine IFN-y is induced indirectly and the production of the T helper type 2 (Th2) cytokines IL-4, IL-5 and TL-13 are inhibited upon administration of the compounds. This activity means that the compounds are useful in the treatment of diseases where upregulation of the Thl response and/or downregulation of the Th2 response is desired. In view of the ability of compounds of Formula Ia to inhibit the Th2 immune response, the compounds are expected to be useful in the treatment of atopic diseases, e.g., atopic dermatitis, asthma,

allergy, and allergic rhinitis; and systemic lupus erythematosis; as a vaccine adjuvant for cell mediated immunity; and possibly as a treatment for recurrent fungal diseases and chlamydia.

The immune response modifying effects of the compounds make them useful in the treatment of a wide variety of conditions. Because of their ability to induce the production of cytokines such as IFN-a and/or TNF-q, the compounds are particularly useful in the treatment of viral diseases and tumors. This immunomodulating activity suggests that compounds of the invention are useful in treating diseases such as, but not limited to, viral diseases including genital warts; common warts; plantar warts; Hepatitis

B; Hepatitis C; Herpes Simplex Virus Type I and Type II; molluscum contagiosum, HIV;

CMV; VZV; intraepithelial neoplasias such as cervical intraepithelial neoplasia; human papillomavirus (HPV) and associated neoplasias; fungal diseases, ¢.g. candida, aspergillus, and cryptococcal meningitis; neoplastic diseases, ¢.g., basal cell carcinoma, hairy cell leukemia, Kaposi’s sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin’s lymphoma, cutaneous T-cell lymphoma, and other cancers; parasitic diseases, ¢.8. pneumocystis carnii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection, leishmaniasis; and bacterial infections, e.g., tuberculosis, mycobacterium avium. Additional diseases or conditions that can be treated using the compounds of the invention include eczema; eosinophilia; essential thrombocythaemia; leprosy; multiple sclerosis; Ommen’s syndrome; discoid lupus; Bowen's disease; Bowenoid papulosis; and to enhance or stimulate the healing of wounds, including chronic wounds.

Accordingly, the invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound of Formula I to the animal. An amount of a compound effective to induce cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, IFN-a, TNF-¢, IL-1, 6, 10 and 12 that is increased over the background level of such cytokines. The precise amount will vary according to factors known in the art but is expected to be a dose of about 100ng/kg to about 50mg/kg, preferably about 10ug/kg to about Smg/kg. The invention also provides a method of treating a viral infection in an animal, and a method of treating a neoplastic disease in an animal, comprising administering an effective amount of a compound of Formula I to the animal. An amount effective to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals. The precise amount will vary according to factors known in the art but is expected to be a dose of 100ng/kg to about 50mg/kg, preferably about 10pg/kg to about Smg/kg. An amount of a compound effective to treat a neoplastic condition is an amount that will cause a reduction in tumor size or in the number of tumor foci. Again, the precise amount will vary according to factors known in the art but is expected to be a dose of about 100ng/kg to about 50mg/kg, preferably about 10ug/kg to about Smg/kg.

The invention is further described by the following examples, which are provided for illustration only and are not intended to be limiting in any way.

Example 1

N-[4-(4-amino-2-ethyl-1 H-imidazo[4,5-c]quinolin-1-yDbutyl]benzenesulfonamide

NH, : DR

YZ bY

HN. &

FC

Triethylamine (1.18 mL, 8.5 mmol) was added to a mixture of 1-(4-aminobutyl)-2- ethyl-1H-imidazo[4,5-c]quinolin-4-amine (2.00 g, 7.1 mmol) and chloroform (200 mL).

The resulting solution was chilled in an acetone/ice bath for 10 minutes. Benzenesulfonyl chloride (0.90 mL, 8.5 mmol) was slowly added over a period of 5 minutes. After 45 minutes 0.2 equivalents of triethylamine was added. After 6 hours the reaction mixture was washed with brine (2 x 250 mL) and with water (1 x 100 mL), dried over magnesium sulfate and then concentrated under reduced pressure. The residue was recrystallized from

N.N-dimethylformamide. The recrystallized material and the filtrate were both slurred with methanol. The resulting solids were isolated by filtration, combined, and then dried in an Abderhalden drying apparatus overnight to provide 0.80 g of N-[4-(4-amino-2-ethyl- 1H-imidazo[4,5-c]quinolin-1 -yl)butyl]benzenesulfonamide as a white solid, m.p. 180.6- 182.0°C. Analysis: Calculated for Cp2H2sNs0;S - 0.25 Hy0: %C, 61.73; %H, 6.00; %N, 16.36; Found: %C, 61.79; %H, 6.04; %N, 16.43.

Example 2

N-[4-(4-amino-2-propyl- 1 H-imidazo[4,5-c]quinolin-1 -yl)butyl]benzenesulfonamide

NH,

P C

HN y &

S ®

Part A

Tert-butyl 4-(2-propyl- 1 H-imidazo[4,5-c]quinolin-1-yl)butylcarbamate (5.00 g, 13.1 mmol) was combined with hydrochloric acid (50 mL of 4.0 M in dioxane) and stirred for 1.5 hours. The reaction mixture was diluted with dichloromethane (~200 mL).

Saturated sodium bicarbonate solution was added until a pH of 8 was obtained. A precipitate formed in the aqueous phase. The layers were separated. The precipitate in the aqueous layer was isolated by filtration, slurried with water and then isolated by filtration to provide 3.6 g of 4-(2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butan-1-amine.

Part B

The material from Part A was combined with chloroform (600 mL) and warmed to 40°C. Triethylamine (3.48 mL, 25 mmol) was added and a solution was obtained.

Benzenesulfonyl chloride (1.60 mL, 12.5 mmol) was added. The reaction mixture was stirred at 40°C overnight. The reaction mixture was cooled to ambient temperature and then concentrated under reduced pressure. The residue was taken up in dichloromethane (~100 mL), washed with water (3 x 125 mL), dried over magnesium sulfate and then concentrated under reduced pressure to provide 3.96 g of N-[4-(2-propyl-1H-imidazo[4,5-

c]quinolin-1-yl)butyl]benzenesulfonamide as a yellow crystalline solid, m.p. 155.9- 157.1°C.

Part C 3-Chloroperoxybenzoic acid (896 mg of 77%) was added over a period of 5 minutes to a solution of N-[4-(2-propyl-1 H-imidazo[4,5-c]quinolin-1- yl)butyl]benzenesulfonamide (1.0 g, 2.4 mmol) in chloroform (100 mL). After 2.5 hours an additional 0.1 equivalent of 3-chloroperoxybenzoic acid was added. After 3 hours the reaction was stored at a reduced temperature overnight. The reaction mixture was washed with saturated sodium bicarbonate solution (3 x 150 mL) and then concentrated under reduced pressure to provide 1.44 g of crude product. This material was recrystallized from methyl acetate to provide 0.67 g of 1- {4-[(phenylsulfonyl)amino]butyl}-2-propyl-15- imidazo[4,5-c]quinolin-5N-oxide as a brown solid, m.p. 203.8-205.2°C.

Part D

Ammonium hydroxide (3.5 mL of 27%) was added to a mixture of the material from Part C and dichloromethane (15 mL). After 10 minutes tosyl chloride (0.35 g) was slowly added over a period of 5 minutes. After 45 minutes the reaction mixture was stored at a reduced temperature over the weekend. An additional 35 mg of tosyl chloride was added and the reaction mixture was stirred for 1 hour. The organic phase was separated and then washed with saturated sodium bicarbonate solution (3 x 80 mL). A precipitate formed in the aqueous phase. This material was isolated by filtration and then recrystallized from methyl acetate. The resulting solid and the filtrate were combined, dissolved in dichloromethane containing a small amount of methanol, and then purified by column chromatography (silica gel eluting with 10% methanol in dichloromethane). The resulting material was purified by column chromatography (silica gel eluting with 0-7.5% methanol in dichloromethane). This material was recrystallized 3 times from methyl acetate to provide 42 mg of N-[4-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1 - yl)butyl]benzenesulfonamide as a white solid, m.p. 158.8-160.8°C. Analysis: Calculated for C23Hz7NsO3S - 0.25 C3HgOs: %C, 62.15; %H, 6.22; %N, 15.59; Found: %C, 62.41; %H, 5.91; %N, 15.41.

Example 3

N-[4-(4-amino-2-hexyl-1 H-imidazo[4,5-c}quinolin-1-yDbutyljbenzenesulfonamide

NH, : Dy ENN yz “

HN : $ 3 TU

Part A

Using the general method of Example 2 Part A, tert-butyl 4-(2-hexyl-1H- imidazo{4,5-c]quinolin-1-yl)butylcarbamate (33.85 g) was hydrolyzed to provide 3.43 g of 4-(2-hexyl-1H-imidazo[4,5-c]quinolin-1-yl)butan-1-amine as an off white solid, m.p. 172.2-174.2°C.

Part B

Using the general method of Example 2 Part B except that the reaction was run at ambient temperature, 4-(2-hexyl-1H-imidazo[4,5-c]quinolin-1-yl)butan-1-amine (1.20 g, 3.7 mmol) was reacted with benzenesulfonyl chloride (429 pL, 3.7 mmol) to provide 0.75 g of N-[4-(2-hexyl- 1 H-imidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide as a light yellow solid, m.p. 137.0-138.1°C.

Part C

Using the general method of Example 2 Part C, N-[4-(2-hexyl-1H-imidazo[4,5- c]quinolin-1-yl)butyl]benzenesulfonamide (0.95 g, 2.0 mmol) was oxidized to provide 1.21 gof crude 1-{4-[(phenylsulfonyl)amino]butyl}-2-hexyl-1H-imidazo[4,5-c]quinolin- 5N-oxide.

Part D

Using the general method of Example 2 Part D, the material from Part C was aminated to provide 118 mg of N-[4-(4-amino-2-hexyl-1H-imidazo[4,5-c]quinolin-1- yl)butylJbenzenesulfonamide as an off white crystalline solid, m.p. 84.8-85.4°C. Analysis:

Calculated for C26H33NsO;S - 0.5 H,O: %C, 63.91; %H, 7.01; %N, 14.33; Found: %C, 63.63; %H, 6.93; %N, 14.80.

Example 4

N-[4-(4-amino-2-propyl- 1 H-imidazo[4,5-c]quinolin-1-yl)butylJmethanesulfonamide

NH, : | TH \ .

H R=

Part A

Using the general method of Example 2 Part B except that the reaction was run at ambient temperature, 4-(2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butan-1 -amine (2.00 g, 7.1 mmol) was reacted with methanesulfonyl chloride (1.65 mL, 21.3 mmol) to provide 1.23 gof N-[4-(2-propy\-1 H-imidazo[4,5-c]quinolin-1-yl)butyljmethanesulfonamide asa light yellow solid, m.p. 133.2-134.6°C.

Part B

Using the general method of Example 2 Part C, N-[4-(2-propyl-1H-imidazo[4,5- c]quinolin-1-yl)butyljmethanesulfonamide was oxidized to provide 1.44 g of crude 1-{4- [(methylsulfonyl)amino]butyl}-2-propyl-1H-imidazo[4,5-c]quinolin-5N-oxide asa light yellow solid.

Part C

Using the general method of Example 2 Part D, the material from Part B was aminated to provide 0.21 g of N-[4-(4-amino-2-propyl- 1 H-imidazo[4,5-c]quinolin-1- yl)butylJmethanesulfonamide as an off white crystalline solid, m.p. 186.5-187.9°C.

Analysis: Calculated for CigH2sNsO:S - 0.25 H20: %C, 56.89; %H, 6.76; %N, 18.43;

Found: %C, 56.95; %H, 6.89; %N, 18.13.

Example 5

N-{4-(4-amino-2-ethyl-1H-imidazo[4,5-clquinolin-1-yl)butyljmethanesulfonamide

NH,

PC

ZN

,

H 8 =

Part A :

Using the general method of Example 2 Part A, tert-butyl 4-(2-ethyl-1H- imidazo[4,5-c]quinolin-1-yl)butylcarbamate (20.69 g) was hydrolyzed to provide 1494 g of 4-(2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butan-1-amine as an off white solid, m.p. 84.8-88.7°C.

PartB

Using the general method of Example 2 Part B, 4-(2-ethyl-1H-imidazo[4,5- c]quinolin-1-yl)butan-1-amine (4.00 g, 14. 9 mmol) was reacted with methanesulfonyl chloride to provide 1.78 g of N-[4-(2-ethyl-1H-imidazo[4,5-c]quinolin-1- yl)butyljmethanesulfonamide as a light yellow solid.

Part C

Using the general method of Example 2 Part C, the material from Part B was oxidized to provide ~2.00 g of crude 1-{4-[(methylsulfonyl)amino]butyl}-2-ethyl-1H- imidazo[4,5-c]quinolin-SN-oxide.

Part D

Using the general method of Example 2 Part D, the material from Part C was aminated to provide 0.42 g of N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1- yl)butyl)methanesulfonamide as a white solid, m.p. 203.3-204.4°C. Analysis: Calculated for C17H23Ns0:S: %C, 56.49; %H, 6.41; %N, 19.37; Found: %C, 56.21; %H. 6.36; %N, 19.09.

Example 6

N-[4~(4-amino-2-methyl- 1 H-imidazo[4,5-c]quinolin-1-yl)butylJbenzenesulfonamide

NH,

NSN

— a “

HN.

AS

Using the general method of Example 1, 1-(4-aminobutyl)-2-methyi-1H- imidazo{4,5-c]quinolin-4-amine (0.50 g, 1.9 mmol) was reacted with benzenesulfonyl chloride (0.24 mL, 1.9 mmol) to provide 0.38 g of N-[4-(4-amino-2-methyl-1H- imidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide as brown granules, m.p. 215.4- 216.0°C. Analysis: Calculated for C,H23Ns0S: %C, 61.59; %H, 5.66; %N, 17.10; Found: %C, 61.24; %H, 5.65; %N, 16.95.

Example 7

N-[4-(4-amino-2-methyl- 1 H-imidazo[4,5-c]quinolin-1-yl)butylJmethanesulfonamide

NH,

NTN

>— 5 he

HN : s. 0°

Using the general method of Example 1, 1-(4-aminobutyl)-2-methyl-1H- imidazo[4,5-c]quinolin-4-amine (1.00 g, 3.7 mmol) was reacted with methanesulfonyl chloride (0.46 mL, 5.9 mmol) to provide 0.16 g of N-[4-(4-amino-2-methyl-1H- imidazo[4,5-c]quinolin-1-yl)butylJmethanesulfonamide as an off white solid, m.p. 229.4- 230.5°C. Analysis: Calculated for CsH2NsO,S - 0.25 H,0: %C, 54.60; %H, 6.16; %N, 19.90; Found: %C, 54.80; %H, 6.24; %N, 19.58.

Example 8

N-[3-(4-amino-2-butyl- 1 H-imidazo[4,5-c]quinolin-1 -yl)propylJmethanesulfonamide

NH, : | IH

VY

Ng

Oo

Part A

Tert-butyl 3-(2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propylcarbamate (~80g) was dissolved in 1,4-dioxane (400 mL) with gentle heating. Hydrochloric acid (55 mL of 4.0 M in 1,4-dioxane) was added in a single portion and the reaction was heated to reflux.

The reaction was monitored by HPLC. Additional acid (150-200 mL) was added and the reaction mixture was refluxed until the reaction was complete. The reaction mixture was cooled to ambient temperature. A solid was isolated by filtration to give ~72 g of 3-(2- butyl-1H-imidazo[4,5-c]quinolin-1-yl)propylamine hydrochloride. This material was combined with that from a previous experiment and then dissolved in water (400 mL).

The solution was neutralized with solid potassium carbonate. AtpH 7 a solid precipitated.

The solid was isolated by filtration and then dissolved in water (1500 mL). The pH was adjusted to pH 10 with solid potassium carbonate. The solution was extracted with chloroform until HPLC analysis showed that no amine remained in the aqueous layer. The organic layers were combined and then concentrated under reduced pressure to provide 45 g of 3-(2-butyl- 1 H-imidazo[4,5-c]quinolin- 1-yl)propylamine.

Part B

Tricthylamine (1.1 g, 10.6 mmol) was added with stirring to a solution of 3-(2- butyl-1H-imidazo[4,5-c]quinolin-1-yl)propylamine (2.00 g, 7.08 mmol) in dichloromethane (~150 mL). Methanesulfonyl chloride (892 mg, 7.79 mmol) was added and the reaction was stirred under nitrogen overnight. The reaction mixture was washed with aqueous 1% sodium bicarbonate solution (3 X 50 mL). The aqueous washes were extracted with dichloromethane (2 x 20 mL). The organics were combined, dried over magnesium sulfate and then concentrated under reduced pressure to provide 1.89 g of N- [3-(2-butyl-1 H-imidazo[4,5-c]quinolin-1-ylpropyl}methanesulfonamide as a light brown solid.

Part C

Using the general method of Example 2 Part C, the material from Part B was oxidized to provide 1.24 g of N-[3-(2-butyl-5-oxido-1H-imidazo[4,5-c]quinolin-1- yl)propyljmethanesulfonamide.

Part D

Using the general method of Example 2 Part D, the material from Part C was animated to provide 690 mg of N-[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1 - yl)propyl]methanesulfonamide as a light tan solid, m.p. 239.2-240.8°C. Analysis:

Calculated for C;sH2sNsO,S: %C, 57.58; %H, 6.71; %N, 18.65; Found: %C, 57.37; %H, 6.78; %N, 18.42.

Example 9

N-[3-(4-amino-2-butyl- 1 H-imidazo[4,5-c]quinolin- 1-yl)propyl]benzenesulfonamide

NH, : IH “ig

S 1

Part A

Using the general method of Example 8 Part B, 3-(2-butyl-1H-imidazo[4,5- c]quinolin-1-yl)propylamine (2.00 g, 7.08 mmol) was reacted with benzenesulfonyl chloride (1.38 g, 7.79 mmol) to provide 2.83 g of N-[3-(2-butyl-1H-imidazo[4,5- c]quinolin-1-yl)propyl]benzenesulfonamide as a light red foam.

Part B

Using the general method of Example 2 Part C, the material from Part A was oxidized to provide 3.28 g of N-[3-(2-butyl-5-oxido-1H-imidazo[4,5-c]quinolin-1- yl)propyl]benzenesulfonamide.

Part C

Using the general method of Example 2 Part D, the material from Part B was animated to provide 1.08 g of N-[3-(4-amino-2-buty}-1 H-imidazo[4,5-c]quinolin-1 - yl)propyl]benzenesulfonamide as a light tan solid, m.p. 210.5-212.0°C. Analysis:

Calculated for C23H27Ns0,S: %C, 63.13; %H. 6.22; %N, 16.01; Found: %C, 62.89; %H, 6.16; %N, 15.74.

Example 10

N-[4-(4-amino-2-hexyl-1 H-imidazo[4,5-c]quinolin-1-yl)butyl}methanesulfonamide

NH, : Di ON > be

HN. & 0°

Part A

Using the general method of Example 1, 4-(2-hexyl-1H-imidazo[4,5-c]quinolin-1- yDbutan-1-amine (1.00 g, 3.1 mmol) was reacted with methanesulfonyl choride (0.48 mL, 6.2 mmol) to provide 1.15 g of N-[4-(2-hexyl-1H-imidazo[4,5-c]quinolin-1- yl)butyljmethanesulfonamide as a white solid.

Part B

Using the general method of Example 2 Part C, N-[4-(2-hexyl-1H-imidazo[4,5- c]quinolin-1-yl)butyl)methanesulfonamide (1.47 g, 3.7 mmol) was oxidized to provide 3.78 g of crude 1- {4-[(methylsulfonyl)amino]buty!}-2-hexyl-1H-imidazo[4,5-c]quinolin- 5N-oxide as a yellow residue.

Part C

Using the general method of Example 2 Part D, the material from Part B was animated to provide 0.28 g of N-[4-(4-amino-2-hexyl-1 H-imidazo[4,5-c]quinolin-1- yl)butyl]methanesulfonamide as an off white solid, m.p. 170.2-171.1°C. Analysis:

Calculated for C21H31NsO,S: %C, 60.40; %H, 7.48; %N, 16.77; Found: %C, 59.97; %H, 7.26; %N, 16.33.

Example 11

N- {8-{4-amino-2-(2-methoxyethyl)- 1 H-imidazo[4,5-c]quinolin-1- ylJoctyl} benzenesulfonamide

NH, ah

ZN

“ ae

Under a nitrogen atmosphere a solution of 1«(8-aminooctyl)-2-(2-methoxyethyl)- 1 H-imidazo[4,5-c]quinolin-4-amine (1.0 g, 2.7 mmol) in dichloromethane (50 mL) was cooled to 0°C. Triethylamine (415 pL, 2.98 mmol) was added followed by benzenesulfonyl chloride (345 pL, 2.71 mmol). The reaction mixture was allowed to warm slowly to ambient temperature and then it was maintained overnight. The reaction mixture was washed with water, dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by column chromatography (50 g of silica gel eluting with 7.5% methanol in dichloromethane). The purified material was recrystallized from propyl acetate, triturated with hexanes, and then dried in a vacuum oven to provide 590 mg of N-{8-[4-amino-2-(2-methoxyethyl)-1H-imidazo(4,5- c]quinolin-1-ylJoctyl} benzenesulfonamide as a yellow powder, m.p. 146-149°C.

Analysis: Calculated for C;7H3sNsOsS: %C, 63.63; %H, 6.92; %N, 13.74; Found: %C, 62.96; %H, 7.03; %N, 13.09. Karl Fisher showed 0.16% or 0.045 mole water. 'H NMR (300 MHz, DMSO-d) § 801 (d, J=7.8 Hz, 1H), 7.78 (m, 2H), 7.65-7.55 (m, SH), 7.45 (m, 1H), 7.28 (m, 1H), 6.71 (s, 2H), 4.50 (m, 2H), 3.83 (m, 2H), 3.5 (broad s, 3H), 3.18 (m, 2H), 2.71 (m, 2H), 1.77 (m, 2H), 1.38-1.17 (m, 10H); 13C NMR (75 MHz, DMSO-ds) 151.7, 151.3, 144.0, 141.0, 132.8, 132.6, 129.5, 127.0, 126.8, 125.9, 121.9, 120.4, 114.9, 70.5, 58.5, 45.3, 42.8, 30.0, 29.2, 28.8, 28.7, 27.5, 26.2, 26.1;

MS m/z S10 (M + H).

Claims

. \ PCT/US2004/020607 CLAIMS:

1. N-{2-[4-amino-2-(ethoxymethyl)- 1 H-imidazo[4,5-c]quinolin-1-yli]-1,1- dimethylethyl } methanesulfonamide, or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim | and a pharmaceutically acceptable carrier.

3. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim | to the animal.

4. Use of a compound or salt of claim 1 in the manufacture of a preparation for treating a viral disease in an animal. 16

5. Use of a compound or salt of claim 1 in the manufacture of a preparation for treating a neoplastic disease in an animal.

6. Use of a compound or salt of claim | in the manufacture of a preparation for inducing cytokine biosynthesis in an animal.

7. A substance or composition for use in a method of inducing cytokine biosynthesis in an animal, said substance or composition comprising a compound or salt of claim 1, and said method comprising administering an effective amount of said substance or composition to the animal.

8. A substance or composition for use in a method of treating a viral disease in an animal, said substance or composition comprising a compound or salt of claim 1, and said method comprising administering a therapeutically effective amount of said substance or composition to the animal.

9. A substance or composition for use in a method of treating a neoplastic disease in an animal. said substance or composition comprising a compound or salt of claim 1 57 AMENDED SHEET

PCT/US2004/020607 and said method comprising administering a therapeutically effective amount of said substance or composition to the animal.

10. A compound according to claim 1, substantially as herein described and illustrated.

11. A composition according to claim 2, substantially as herein described and illustrated.

12. A method according to claim 3, substantially as herein described and illustrated.

13. Use according to any one of claims 4 to 6, substantially as herein described and illustrated.

14. A substance or composition for use in a method of treatment according to any one of claims 7 to 9, substantially as herein described and illustrated.

15. A new compound, a new composition, a new non-therapeutic method of treatment, a new use of a compound a claimed in claim 1, or a substance or composition for a new use in a method of treatment, substantially as herein described. 58 AMENDED SHEET